Community Assessment of COPD Health Care (COACH) study: a clinical audit on primary care performance variability in COPD care

María Abad-Arranz, Ana Moran-Rodríguez, Enrique Mascarós Balaguer, Carmen Quintana Velasco, Laura Abad Polo, Sara Núñez Palomo, Jaime González Rey, Ana María Fernández Vargas, Antonio Hidalgo Requena, Jose Manuel Helguera Quevedo, Marina García Pardo, Jose Luis Lopez-Campos, and on behalf of the COACH study investigators

Abstract

Background: A thorough evaluation of the adequacy of clinical practice in a designated health care setting and temporal context is key for clinical care improvement. This study aimed to perform a clinical audit of primary care to evaluate clinical care delivered to patients with COPD in routine clinical practice.

Methods: The Community Assessment of COPD Health Care (COACH) study was an observational, multicenter, nationwide, non-interventional, retrospective, clinical audit of randomly selected primary care centers in Spain. Two different databases were built: the resources and organization database and the clinical database. From January 1, 2015 to December 31, 2016 consecutive clinical cases of COPD in each participating primary care center (PCC) were audited. For descriptive purposes, we collected data regarding the age at diagnosis of COPD and the age at audit, gender, the setting of the PCC (rural/urban), and comorbidities for each patient. Two guidelines widely and uniformly used in Spain were carefully reviewed to establish a benchmark of adequacy for the audited cases. Clinical performance was analyzed at the patient, center, and regional levels. The degree of adequacy was categorized as excellent (> 80%), good (60–80%), adequate (40–59%), inadequate (20–39%), and highly inadequate (< 20%).

Results: During the study 4307 cases from 63 primary care centers in 6 regions of the country were audited. Most evaluated parameters were judged to fall in the inadequate performance category. A correct diagnosis based on previous exposure plus spirometric obstruction was made in an average of 17.6% of cases, ranging from 9.8 to 23.3% depending on the region. During the audited visit, only 67 (1.6%) patients had current post-bronchodilator obstructive spirometry; 184 (4.3%) patients had current post-bronchodilator obstructive spirometry during either the audited or initial diagnostic visit. Evaluation of dyspnea was performed in 11.1% of cases. Regarding treatment, 33.6% received no maintenance inhaled therapies (ranging from 31.3% in GOLD A to 7.0% in GOLD D). The two most frequently registered items were exacerbations in the previous year (81.4%) and influenza vaccination (87.7%).

Conclusions: The results of this audit revealed a large variability in clinical performance across centers, which was not fully attributable to the severity of the disease.

Keywords: COPD, Clinical audit, Primary care, Quality of care, Variability
How this fits in
To the best of our knowledge, this is the first ever clinical audit of primary clinical care delivery to COPD patients in Spain. The results of this study indicate that there is considerable variability in clinical performance, not completely attributable to the severity of the disease. Identification of the determinants of this variability will help us understand clinical behavior, and establish strategies to strengthen clinical practice for COPD in primary care.

Background
Measurement of the adequacy of clinical practice in a designated health care setting and temporal context is key for clinical care improvement. In this regard, clinical audits provide an innovative tool to assess the quality of care, playing a significant role in highlighting the gaps between the recommended practices and the care that patients actually receive [1]. Accordingly, audits and feedback have shown to improve health care for different disease conditions [2].

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with extrapulmonary implications that poses a major burden for the patient and the health system [3, 4], with a high prevalence [5], morbidity and mortality [6] rate. Hence, the care for these patients should engage the highest quality standards due to its potential impact on the lives of patients, and relatives, alongside the strain on resources. Therefore, COPD is one of the diseases in which clinical audits are deemed to be of special relevance.

Until the last few years, clinical audits for COPD were not frequently carried out. Over the last several decades, the United Kingdom [7], followed by Spain [8, 9], have been leading the audit process for COPD in Europe. Additionally, several countries have recently started their own audit projects [10–12], like the recent European Clinical COPD Audit in 13 European countries [13, 14]. In Spain, the so-called AUDIPOC network evaluated clinical care in patients hospitalized due to COPD [15] and recent initiatives have explored the clinical performances in specialized respiratory outpatient clinics [16]. These audits have provided valuable information about medical interventions in hospital wards for patients admitted with COPD exacerbation [14], the resources available [17], and the interrelationship between resources and clinical practice [15, 16]. Although not formally labelled as clinical audits, previous analyses have been done describing different aspects of clinical performance in primary care using different methodological approaches [18–20].

The information regarding how COPD patients are treated in the primary care setting is essential and would provide very relevant information on the process of care. It might also reveal the key areas wherein improvements are required in order to complete the picture obtained in secondary care audits. Therefore, formal clinical audits in primary care are emerging to evaluate clinical performance in this setting using a standardized methodology (https://www.rcplondon.ac.uk/COPD). Based on our previous audit experiences, we have developed a clinical audit for COPD patients in the primary care setting in Spain. In this manuscript, we describe the full methodology and main results of this clinical audit regarding guideline adherence in primary care centers (PCC) in Spain. The results of this audit will serve as a basis for an improvement in health care delivery for COPD patients.

Methods
The Community Assessment of COPD Health Care (COACH) study was an observational, cross-sectional, multicenter, national, retrospective, and non-interventional clinical audit aimed at evaluating the clinical care delivered to COPD patients in randomly selected primary care centers in Spain. This is the result of a joint project between the Spanish Primary Care Respiratory Group (GRAP) and the Spanish Society of Pneumology and Thoracic Surgery (SEPAR). The enrolment of participants and data collection was performed retrospectively.

Governance
The COACH study was managed by a steering committee comprising two primary care physicians and two pulmonologists, with expertise in COPD care and clinical audits. One of them acted as a project manager for the daily oversight of the project. Each participating region selected a primary care physician to act as regional project coordinator. Altogether, the steering committee including the project manager and all regional representatives formed the expert panel, an operational group that was responsible for ensuring the success of the data collection and which provided feedback on the process and suggested improvements through regular face-to-face meetings and teleconferences. Within each participating region, a number of PCC were selected, and primary care physicians were appointed as local investigators responsible for local data collection on patients and the organization of care.

Selection of centers
A list of all PCC in Spain was obtained from the official web pages of regional health systems in the country and entered into an Excel spreadsheet (Microsoft Corporation, Redmond, WA, USA). Since the size of each region and their respective number of provinces varied, the arbitrary proportion of PCC to be selected in each province was 10%, as determined by the expert panel.
Comorbidities were evaluated by Charlson [21] and defined as areas with a population of less than 25,000. PCC (rural/urban), and comorbidities. Rural areas were diagnosed with COPD and at audit, gender, setting of the place in Madrid on September 13th, 2014, and by email and teleconferences thereafter to refine the final version. A record of the current pharmacological and non-pharmacological therapeutic scheme, adverse events, compliance, and inhaler satisfaction were also judged to be of relevance during the clinical interview of COPD patients. Inhaler satisfaction did not specifically reflect the correct inhaler technique, but was extracted from the clinical records if the general satisfaction of the patient with the inhaler was recorded.

The accuracy of the diagnosis was confirmed by previous exposure to inhalational irritants plus a post-bronchodilator non-reversible obstruction on spirometry. Information regarding previous exposure to noxious particles or gases included a history of active smoking, passive smoking, occupational exposure, biomass exposure or any other form of exposure judged to be relevant to the diagnosis as reflected in the medical record. Limited reversal of airflow was assessed by post-bronchodilator spirometry; however, after the first evaluation we noted that most patients had only a pre-bronchodilator spirometry. Therefore, we used pre-bronchodilator values for those cases without post-bronchodilator spirometry values. The obstruction also had to be present during the last recorded visit to consider it non-reversible.

From a therapeutic point of view, the use of a long acting bronchodilator (LABD), either a long-acting β2 agonist (LABA) or a long-acting muscarinic antagonist (LAMA), as the basis for pharmacological treatment, the compliance with the GOLD recommendations in pharmacological prescription, adequate recommendation on non-pharmacological treatments including advising to quit smoking, vaccine recommendations, and exercise recommendations, were recorded.

For the adequacy of maintenance inhaled therapies, we assumed the following scenarios to reflect incorrect prescriptions: GOLD 2017 B-D patients without any medication recorded, any patient on inhaled corticosteroids (ICS) alone, and those treatment plans that duplicated drugs in combined and single therapies.

Protocol of the study
Information was recorded by an ad-hoc built database via a centralized web page. A freelance web programmer with experience in database management was commissioned to create this website and the structure of the database. The website was organized as a hierarchical tool with different levels of responsibilities and rights to
process data. Only members of the steering committee had full access to all data and the right to process them. At the regional level, there was a hierarchical access for regional administrators down to the level of local investigators coordinating the local data collection. To minimize a potential bias due to several auditors evaluating different medical records from different systems, we trained the auditors on how to proceed during data gathering and established limitations and rules in the database.

Data was collected from January 1, 2015 to December 31, 2016. The doctors in charge of the patients were unaware of the audit. During this period, the local investigator consecutively reviewed the medical records for confirmed cases of COPD and recorded the audit information for 80 cases per PCC. Accordingly, the selection of cases was based on a registered diagnosis of COPD in the medical record. No diagnostic criteria were considered for inclusion, since assessing the quality of the diagnoses was an outcome of the audit. The classification of patients as having COPD within the medical records was sufficient to include them in the audit. No exclusion criteria were defined.

Ethical considerations
The study complied with the ethical requirements of the Helsinki Declaration regarding studies involving human subjects and with the Spanish regulation on data protection and confidentiality (Spanish Organic Law 15/1999 of December 13, on the Protection of Personal Data). The study was evaluated by the Spanish Agency for Medicine and Health Products and classified as a not post-commercialization observational study. The main ethical approval was obtained from the regional ethical committee of Andalusia region (approval number 02/2014) and any other participating region if required based on regional legislation. The clinical records were anonymized in the database by assigning a numerical code through an algorithm. No personal information that could be used directly or indirectly to identify an individual was entered. The relationship between the audit code and the clinical history number was kept locally, being the responsibility of the local investigator to avoid duplications. Because of the retrospective nature of the study, the anonymization of data, and the lack of active research interventions, the need for informed consent was waived. The ethics committee was aware of these circumstances clearly explained in the protocol, and approved this procedure.

Statistical analysis
All computations were performed using SPSS Statistics version 20.0 (IBM Corporation, Armonk, NY, USA). Before performing any analysis, the database was evaluated for quality. The values that were extreme from a clinical point of view, missing, or inconsistent were returned to the investigators for correction. The clinical variables are presented as means and standard deviations or absolute and relative frequencies, as appropriate, at the patient level. The variability was expressed by using the inter-regional range, which represents the highest and lowest mean values from the participating center at the regional level, and the inter-center range, representing the highest and lowest mean values from the audited cases at the PCC level. Five centers with less than 10 included cases were not considered in calculating the inter-center range. Due to the low number of cases in the Balearic Islands, they were not considered in the calculation of the inter-regional range. The significance of this variability among the different participating centers and regions was explored for quantitative variables by the ANOVA test, after checking the equality of the variances with the Levene test. If the homoscedasticity assumption was not met, we used the Welch test. For the analysis of the categorical variables, we used the Chi-square test. The alpha error was set at 0.05 (two-tailed).

Based on previous experiences by our group [16], the degree of adequacy between the audited information and the recommendations of the consulted documents was categorized as excellent (> 80%), good (60–80%), adequate (40–59%), inadequate (20–39%), and highly inadequate (< 20%). A subgroup analysis was performed on those cases providing data on disease subtypes according to GOLD 2017 patient types to explore the distribution of treatments among them.

Results
During the study, 4307 cases from 63 PCC in 6 regions of the country were finally audited (Fig. 1). The description is summarized in Table 1. This was a cohort of COPD patients, with male gender predominance, in the 7th decade of life, with a considerable number of patients being active smokers and having moderate lung function impairment. Overall, there was a considerable variability among the different regions of the country and PCCs, which was significant for most variables. Interestingly, the variability of forced expiratory volume in 1 s (FEV1) was not significant.

The results of the clinical audit in terms of diagnostic and clinical evaluation are summarized in Table 2. The diagnoses were correct in a minority of cases. In the audited visit, only 67 (1.6%) cases had a current post-bronchodilator obstructive spirometry. If the diagnostic spirometry was included, 184 (4.3%) cases had a post-bronchodilator obstructive spirometry either in the audited visit or in the initial diagnostic visit. However, when the inter-regional and inter-center ranges were analyzed, this result improved in some centers, although
none of them reached the threshold of 80% considered to be excellent. The consideration of symptoms as an added criterion for assessing the diagnoses worsened the results since a considerable number of audited cases did not record chronic symptoms. With considerable variability, dyspnea, chronic bronchitis, and asthma symptoms were not adequately registered in most audited cases, although some centers performed than others. Interestingly, exacerbations were more frequently registered in as many as 80% of the cases audited.

The most frequently registered non-pharmacological therapies were vaccinations. Interestingly, current smoking habit was registered in 43.5% of audits, similar to the value for registered exercise. Three other key aspects of non-pharmacological evaluation, namely treatment adherence, adverse effects, and inhaler satisfaction, were rarely registered.

Regarding the complementary tests, spirometry was performed in a minority of cases. Alpha 1-antitrypsin determination was the only item showing no significant variability among regions, and this was anecdotal. Other tests and assessments including computed tomography scan and sputum eosinophils, as well as health-related quality of life, were more rarely obtained from the medical records (data not shown).

The use of current therapies for COPD is summarized in Table 3. The most frequently prescribed non-pharmacological treatment was influenza vaccination. Only in 24.4% of audits was it registered that the patients had quitted smoking. The distribution of pharmacological treatment is shown in Fig. 2. Triple therapy, followed by the combined use of an ICS and a LABD, was most commonly used during the audit period. In the whole cohort, 40 (0.9%) cases were receiving non-combined ICS-LAMA therapy. GOLD 2017 patient types were identified in 436 (10.1%) cases, and the distribution of inhaled therapies in this group of patients is shown in Fig. 3. Altogether, the treatments including an ICS by GOLD 2017 patient types were: GOLD A 50 (25.3%), GOLD B 47 (54.7%), GOLD C 35 (53.0%), and GOLD D 57 (66.3%). The percentage of GOLD 2017 patient types who did not receive any maintenance inhaled therapies was: GOLD A 31.3%, GOLD B 8.1%, GOLD C 9.1%, GOLD D 7.0%.
The results of this study indicate that there is considerable variability in clinical performance that cannot completely be attributed to the severity of the disease. Most evaluated parameters were judged to fall under inadequate performance, except two (i.e., registration of influenza vaccination, and registration of exacerbations in the previous years) that were classified as excellent.

There is increasing evidence and awareness that patients with various health problems do not consistently receive the recommended care despite the multitude of clinical practice guidelines and there is a gap between the clinical care provided and that recommended by practice guidelines [29]. In this regard, clinical audits constitute a valuable tool to assess clinical performance and set the basis for future improvement. The present study represents an innovative initiative to perform a national clinical audit of COPD care in primary care in Spain, as in other countries (https://www.rcplondon.ac.uk/COPD).

**Table 1** Characteristics of the audited cases (n = 4307)

| Variables                             | Average (patient level) | Inter-center range | Inter-regional range |
|---------------------------------------|-------------------------|--------------------|----------------------|
|                                       |                         | Range              | P value a            | Range              | P value a            |
| Male gender (n)                       | 3159 (73.3)             | 35.7–93.8          | < 0.001              | 67.9–78.1          | < 0.001              |
| Age (years)                           | 71.1 (12.7)             | 61.9–80.2          | < 0.001              | 67.2–73.3          | < 0.001              |
| Rural communities                     | 1771 (41.1)             | –                  | –                    | 5.8–74.6           | < 0.001              |
| Active smoker (n)                     | 1152 (26.7)             | 4.8–80.8           | < 0.001              | 20.7–41.9          | < 0.001              |
| Ex-smokers (n)                        | 1127 (26.2)             | 6.1–40.0           | < 0.001              | 0.0–76.5           | < 0.001              |
| Life-long never smokers (n)           | 579 (13.4)              | 0.0–84.6           | < 0.001              | 8.3–19.0           | < 0.001              |
| Previous smoking status unknown (n)   | 1449 (33.6)             | 16.8–51.6          | < 0.001              | 2.2–88.1           | < 0.001              |
| Tobacco history (pack-years)          | 44.2 (48.6)             | 9.0–100            | < 0.001              | 29.9–48.8          | 0.045                |
| Comorbidities (Charlson index)        | 2.2 (1.4)               | 1.5–3.2            | < 0.001              | 1.9–24             | < 0.001              |
| Comorbidities (COTE index)            | 1.1 (1.8)               | 0.5–1.8            | < 0.001              | 0.8–1.4            | 0.003                |
| Comorbidities: cardiac b (n)          | 1280 (29.7)             | 13.3–63.6          | < 0.001              | 26.5–32.5          | 0.076                |
| Comorbidities: vascular c (n)         | 913 (21.2)              | 0–40.0             | < 0.001              | 15.7–24.9          | < 0.001              |
| Comorbidities: neoplasms (n)          | 476 (11.1)              | 0–31.3             | < 0.001              | 2.9–15.4           | < 0.001              |
| Comorbidities: sleep apnea (n)        | 201 (4.7)               | 0–20.3             | < 0.001              | 0.78               | < 0.001              |
| Comorbidities: eyedrops use (n)       | 54 (1.3)                | 0–18.2             | < 0.001              | 0.9–2.8            | 0.018                |
| Comorbidities: psychiatric drugs d (n)| 501 (11.6)              | 0–38.2             | < 0.001              | 6.8–15.8           | < 0.001              |
| Comorbidities: prostatic hyperplasia (n)| 725 (16.8)       | 0–33.3             | < 0.001              | 8.8–21.7           | < 0.001              |
| Body mass index (kg/m²)               | 29.2 (5.5)              | 26.7–37.1          | < 0.001              | 28.4–30.9          | 0.004                |
| Current FEV1 (mL) d                    | 1690 (604)              | 810–2720           | 0.115                | 1640–1794          | 0.744                |
| Current FEV1 (%) d                    | 64.3 (22.8)             | 39.0–97.0          | 0.037                | 21.0–25.7          | 0.136                |
| Current FEV1/FVC (%) d                | 62.3 (13.2)             | 69.0–51.0          | 0.741                | 60.2–65.1          | 0.249                |

Data are expressed as mean (standard deviation) or absolute (relative) frequencies, as needed

* FEV1 forced expiratory volume in the first second
* Calculated by Chi-squared test or ANOVA to test for variability
* Includes coronary artery disease, heart failure, and atrial fibrillation or flutter
* Includes coronary artery disease, peripheral vascular disease, and cerebrovascular disease
* Obtained from post-bronchodilator spirometry, and if not available, from pre-bronchodilator spirometry
* Includes anxiolytics, antidepressants, and antipsychotics

**Discussion**

The results of this study indicate that there is considerable variability in clinical performance that cannot completely be attributed to the severity of the disease. Most evaluated parameters were judged to fall under inadequate performance, except two (i.e., registration of influenza vaccination, and registration of exacerbations in the previous years) that were classified as excellent.

There is increasing evidence and awareness that patients with various health problems do not consistently receive the recommended care despite the multitude of clinical practice guidelines and there is a gap between the clinical care provided and that recommended by practice guidelines [29]. In this regard, clinical audits constitute a valuable tool to assess clinical performance and set the basis for future improvement. The present study represents an innovative initiative to perform a national clinical audit of COPD care in primary care in Spain, as in other countries (https://www.rcplondon.ac.uk/COPD).

The diagnosis of COPD is of utmost importance. The latest version of the GOLD criteria requires three main components for a correct diagnosis including respiratory symptoms, previous exposure to noxious gases and particles, and obstruction on post-bronchodilator spirometry. Our results showed that in the primary care setting, some of these three criteria were missing in a high proportion of patients. Even if older versions of the GOLD criteria are applied (which do not categorically state the requirement of symptoms as a diagnostic sub-criterion) and the results of pre-bronchodilator spirometry in the absence of post-bronchodilator spirometry results are used, the number of acceptably diagnosed cases would still be low, only on the basis of previous exposure and the presence of obstruction. In this context, the availability and use of spirometry in primary care is essential. In the UK, a recent analysis pointed out that although the quality of spirometry procedure undertaken in primary care is high, this does not reflect the quality of interpretation, suggesting an unmet training target in
primary care [19]. In Spain, although most centers received training for conducting spirometry tests, this was routinely done in less than 40% of centers and the mean number of spirometries conducted per week in the primary care settings was 5.6 (ranging from 2.0 to 8.8 depending on the region) [30]. In the US, spirometry is infrequently assessed even in those more severe patients receiving triple therapy [31]. Interestingly, the performance is better in other countries [18]. The consequences of this incorrect diagnosis impact several domains, with many patients receiving pharmacological treatment that is not needed and a potential for drug-related adverse effects, giving health services to wrong patients, subjecting patients to additional and often unnecessary tests, labeling them as sick or at-risk, telling them to modify their daily living habits, or insisting on monitoring them regularly. Additionally, it also impacts the health system, leading to potential extra costs [32]. Consequently, in the light of our results, the clinician should be aware of the diagnostic criteria for COPD and consider respiratory symptoms, exposure to risk factors and spirometry results before firmly establishing this diagnosis.

In 33.6% of cases, there was no information on maintenance inhaled therapies. This finding has been previously reported but with a considerable difference. A recent analysis of the medical records of 3376 patients from a general practice in Denmark revealed that 74.4% of them did not receive any maintenance inhaled medication even after the spirometric diagnosis of COPD [33]. In the United Kingdom 28% of the 20,154 patients whose medical records were analyzed [20], received no initial pharmacological treatment. The number was reported to be as low as 20% in another study, which looked into the records of of 29,815 patients [34]. In Sweden, this figure was far below 10% in secondary care [35]. In the United States, it has been reported that 55%
of such patients did not receive inhaled maintenance therapy [36]. The reasons for this finding fall outside the scope of the present study and would require a specific debate and an ad-hoc investigation.

Double bronchodilation was probably underestimated during the period of the audit, as double bronchodilator therapy was not widely available at the time. Only one (indacaterol-glycopyrronium) of the 4 double bronchodilator medications later approved in Europe for the treatment of COPD [37] was available in Spain at that time. In spite of this, the number of patients receiving LABA-LAMA combination therapies was slightly higher than those on single therapies, suggesting that the use of LABA-LAMA combinations may have continued to increase in subsequent years. A fact which was confirmed in subsequent audits [16].

Previous studies have reported the overuse of ICS, as well as an increase in their use for all GOLD patient types. Price et al. have reported the use of ICS in 50% of COPD patients in primary care settings in the United Kingdom [38]. In the present study, ICS-containing regimens were used in approximately 42.2% of all patients, ranging from 25.3% in GOLD 2017 A to 66.3% in GOLD 2017 D. Most patients receiving triple therapy were on a LABA-ICS + LAMA combination. Although the efficacies of both forms of triple therapy (LABA-ICS + LAMA vs. LABA-LAMA + ICS) may be similar [39], their appropriateness for use may have changed now in the light of recent studies and recommendations [40, 41]. Interestingly, a recent real-world prescription analysis in the UK, demonstrated inappropriate prescribing of triple therapy and confirmed that starting patients on ICS plus LABA results in the inevitable drift to overuse of triple therapy [42]. Although in the present study only 10% of cases could be classified according to GOLD 2017 patient types, this scenario represents an improvement

| Table 3 Audit results regarding administration of treatments (n = 4307) |
|---------------------------------------------------------------|
| Variables | Average (Patient level) | Inter-center range | Inter-regional range |
|-----------|-------------------------|--------------------|---------------------|
| Non-pharmacological treatments                               |                         |                     |                     |
| Recommendations about not smoking                           | 1051 (24.4)            | 0–76.5             | < 0.001             |
| Perform some exercise                                       | 958 (22.2)             | 0–84.7             | < 0.001             |
| Influenza vaccination administered                         | 2869 (66.6)            | 34.1–95.2          | < 0.001             |
| Pneumococcal vaccination administered                      | 1620 (37.6)            | 0–82.3             | < 0.001             |
| Inhaled maintenance therapies                               |                         |                     |                     |
| No inhaled treatment/not available                          | 1446 (33.6)            | 8.8–54.9           | < 0.001             |
| One long-acting bronchodilator                              | 653 (15.2)             | 0–33.3             | < 0.001             |
| LAMA + LABA b                                                | 392 (9.1)              | 0–35.3             | < 0.001             |
| ICS alone                                                   | 67 (1.6)               | 0–11.1             | 0.018               |
| ICS + one long-acting bronchodilator                        | 804 (18.7)             | 0–38.2             | < 0.001             |
| Triple therapy                                              | 945 (21.9)             | 0–50.0             | < 0.001             |
| ICS-containing regimens                                     | 1816 (42.2)            | 12.5–66.3          | < 0.001             |
| Incorrect prescription c                                     | 224 (5.2)              | 0–14.7             | < 0.001             |
| Oral maintenance therapies                                  |                         |                     |                     |
| Roflumilast                                                 | 58 (1.3)               | 0–7.7              | < 0.001             |
| Mucolytics                                                  | 96 (2.2)               | 0–26.7             | < 0.001             |
| Antibiotics                                                 | 29 (0.7)               | 0–6.7              | < 0.001             |
| Methylxanthines                                             | 97 (2.3)               | 0–17.6             | < 0.001             |
| Home-based therapies                                        |                         |                     |                     |
| Long-term oxygen therapy                                    | 175 (4.1)              | 0–18.8             | < 0.001             |
| Home mechanical ventilation                                 | 35 (0.8)               | 0–10.0             | < 0.001             |
| Nebulized therapy                                           | 121 (2.8)              | 0–22.4             | < 0.001             |

Data are expressed as absolute (relative) frequencies in reference to the whole cohort unless otherwise specified.

- LABA: long-active β2 agonist, LAMA: long-acting muscarinic antagonist, ICS: inhaled corticosteroids
- a Calculated by Chi-squared test or ANOVA to test for variability
- b Combined in one single inhaler or not. Only indacaterol-glycopyrronium combination was available in the country at the time of the audit
- c Per the protocol, the following scenarios were deemed to represent incorrect prescriptions: GOLD 2017 B-D patients without any medication registered, any case of ICS use alone, and those prescriptions that duplicated drugs in combined or single therapies
**Fig. 2** Distribution of maintenance inhaled therapies. ICS: inhaled corticosteroids; LABA: long-acting $\beta_2$ agonist; LABD: long-acting bronchodilator; LAMA: long-acting muscarinic antagonist.

**Fig. 3** Distribution of maintenance inhaled therapies according to GOLD 2017 groups. Only in 436 cases out of the total 4307 cases audited (10.1%), GOLD classification could be assessed, based on exacerbation frequency and symptoms. ICS: inhaled corticosteroids; LABA: long-acting $\beta_2$ agonist; LABD: long-acting bronchodilator; LAMA: long-acting muscarinic antagonist; CAT: COPD Assessment Test; mMRC: modified Medical Research Council.
from previous reports on the use of ICS in COPD. Recent studies have shown that ICS prescription in GOLD A/B patients is common, with significant regional variation independent of lung function impairment [34]. Despite the reported overuse of triple therapy [42, 43], we found an increase in their prescription with the progression of GOLD 2017 patient types. Notably, although not explicitly recommended in the guidelines, some patients were receiving LAMA-ICS combination therapy. Only a few trials have evaluated this combination in COPD patients [44, 45].

Overall, there was a considerable variability among the different regions of the country and PCCs, which was significant for the majority of variables due to the large sample size. Interestingly, the variability of FEV₁ was not significant, suggesting that the variability found is not related to disease severity as measured by this parameter. Previous studies have demonstrated significant variability in the processes and outcomes of COPD care in different settings [46, 47]. It has been shown that this variability in clinical practice is not exclusively influenced by clinical presentation or the resources available, but that there is a so-called cluster effect [15]. The cluster effect indicates that patients with similar characteristics may experience different processes of care and outcomes, depending on the center because they are subject to distinct common contextual influences, beyond resources or standards of care, like the characteristics of the catchment area, such as socioeconomic status, and utilization of health services or COPD specific criteria in a determined clinical situation. In our audit we found an extremely important variability in clinical practice that should be explored in the future. The idea behind quality of care is that all patients with the same condition should be managed similarly. However, this is very complex in clinical practice since the clinical presentation of chronic diseases is variable, the perception by the patients varies and is influenced by many personal aspects, and the response to therapies is also variable. Therefore, describing the variability is essential to really understand its potential implications allowing us to seek specific approaches in the future.

Clinical audits have gained traction in healthcare systems as a way of obtaining information on the clinical care being provided, as shown by a recent qualitative study in a primary care setting [18]. This information is of interest to both funding bodies, who want to ensure that the care they finance is of the highest possible standard, and for patients who hope to receive safe and effective healthcare. However, despite evidence from several studies on audit and feedback, few data are currently available on how to use this information. A recent systematic review assessed the effectiveness of audit and feedback and reported an inconsistent picture; some evaluations obtained positive results, whereas others did not [48]. In this context, feedback from the audited information constitutes a key step in improving clinical practice [49]. Probably the most extended initiative is that of care bundles that have been successfully applied in health care [50]. The applicability of these care bundles or any other initiative aiming to improve primary health care in COPD patients should be assessed next.

The strengths of this project are the potential to raise the profile of COPD, and provide an opportunity to promote respiratory medicine in the community, offer suggestions and recommendations on organization of care for the future COPD management guideline, and develop educational resources to support improved clinical practice in all areas, especially those identified as poor practice. Also, the audit provides a formal documentation of the difference between recommended best practices and the status quo, thereby identifying areas requiring improvement.

To interpret the results correctly, several key aspects of the methodology must be considered. First, the audit assessed interventions that had already been performed, and not the results thereof. For instance, it assessed if the physician in charge registered the degree of dyspnea, rather than the intensity of dyspnea after intervention. Thus, the aim of the audit was not to have an idea of the clinical situation of the patient but to have an idea of the clinical performance of the practitioner. Second, the clinical audit made its evaluation from the contents of medical records. Therefore, what was not documented was not evaluated. This does not imply that no intervention had taken place. Accordingly, the estimates presented here were those inferred from the medical record and we may have underestimated the actual figures. The need to record every aspect of clinical practice in the medical record has been previously emphasized [51], and our results further ascertain such need. Third, although medical records are electronic in all participating PCC, the application and interface to access the data were different in different regions of the country. Thus, different investigators interacted with different systems, which may have influenced the availability of the data. To check for the quality of these data, the values that were extreme, missing, or inconsistent were returned to the investigators for correction. Fourth, the concept of incorrect prescription could be questionable or misleading is based on the GOLD document. GOLD patient types constitute a way of categorizing patients to ease the selection of the therapeutic approach [40]. However, the magnitude of the impact of the disease can vary considerably within one type [52]. Also, patients with specific clinical phenotypes or presentations might be classified under the same GOLD type, and therefore warrant a change in therapy [53]. Therefore, to confirm those cases with incorrect prescriptions, we selected
those cases with specific criteria showing incorrect treatment strategies. Finally, the present paper describes great variability in clinical practice. The next issue to solve would be to do an analysis of the confounding or explanatory variables for such a wide range of variables, which will be a matter of another analysis.

In summary, our results show areas of greatest concerns in COPD care. Clinicians should be aware that only a correct diagnosis makes it possible to select proper pharmacological treatment for COPD, that COPD cannot be diagnosed without proving irreversible obstructive pattern on post-bronchodilator spirometry, that cigarette smoke exposure and especially duration of smoking in years is an important risk factor for the disease and should be systematically evaluated, that smoking cessation, physical activity, nutrition, vaccinations as well as recognition and treatment of comorbidities are key in the management of the disease beyond the use of bronchodilators, and that the use of the different pharmacological approaches should be patient-tailored, and confined to those who do get the benefit from them with no harm.

Conclusions

In conclusion, the present analysis, to the best of our knowledge, is the first ever clinical audit carried out in Spanish PCC to evaluate clinical performance in stable COPD patients. The results show that there is a considerable variability in clinical performance not fully attributable to the severity of the disease and that the majority of the evaluated parameters fell in the range of inadequate performance. A study of the determinants of this variability will help us to understand clinical behavior, and establish strategies to strengthen the clinical practice of COPD management in primary care.

Abbreviations

COACH: Community Assessment of COPD Health Care; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; GesEPoC: Spanish National Guideline for COPD; GINA: Global Initiative for Asthma; GOLD: Global Initiative for Obstructive Lung Disease; GRAP: Spanish GesEPOC; ICS: inhaled corticosteroids; LABA: long-acting ß2 agonist; LABD: long-acting bronchodilator; LAMA: long-acting muscarinic antagonist; PCC: primary care centers; SEPAR: Spanish Society of Pneumology and Thoracic Surgery

Acknowledgements

The coordinators of the project thank Boehringer Ingelheim for funding the project and to all the local investigators in each participating primary care center for the hard work and for participating in data collection with enthusiasm and dedication.

COACH CONSORTIA: Steering scientific committee: Jose Luis Lopez-Campos. Hospital Universitario Virgen del Rocio; Ana Morán Rodríguez. UGC-DCCU Bahía de Cádiz-La Janda; Enrique Mascarós Balaguer. Centro de Salud Fuente de San Luis; María Abad Arranz. Hospital Universitario Virgen del Rocio. Regional coordinators: Ana Mª Fernández Vargas. Centro de Salud La Victoria (Málaga); Antonio Hidalgo Requena. Centro de Salud de Lucena (Cádiz); Carmen Quintana Velasco. Centro de Salud Grañén (Huesca); Laura Abad Pol. Centro de Salud Illueca, sector Calatayud (Zaragoza); Marina García Pardo. Centro de Salud de Inca (Mallorca); José Manuel Helguera Quevedo. Centro de Salud Bajo Asón (Cantabria); Jaime González Rey. Centro de Salud Matamá (Vigo); Sara Núñez Palomo. Centro de Salud Torrelaguna (Madrid). List of investigators by region: ANDALUSIA: Ana María Fernández Vargas. Centro de Salud La Victoria (Málaga); Beatriz Elosa Mazá. Centro de Salud de El Egipto (Almería); Cristina Pulido Vázquez. Centro de Salud Antequera-Estación (Málaga); Eloy de Haro Muñoz. Centro de Salud de Cenes de la Vega (Granada); Enrique Pérez Ortiz. Centro de Salud de Almuñécar (Granada); Fernando López Verde. Centro de Salud Delicias (Málaga); Francisco José Guijarro Hidalgo. Centro de Salud de Cárta (Málaga); Irene Martínez Ríos. Centro de Salud Delicias (Málaga); Jose María López López. Centro de Salud de Tabernas (Almería); Juan Antonio Lara González. Centro de Salud Antequera-Estación (Málaga); Juan Carlos Navarro González. Centro de Salud de Cárta (Málaga); Manolo Del Rey Pérez. Centro de Salud de El Egipto (Almería); Manuel Resa Alcalá. Centro de Salud Antequera-Estación (Málaga); Ramon Nicolás Franco Reins. Centro de Salud de Tabernas (Almería); Raúl Rabanedo Bueno. Centro de Salud de El Egipto (Almería); José Galván Espinosa. Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO); José Miguel Cerón. Responsable investigación en Jaén; Antonio Nuñez Montenegro. Unidad de investigación Antequera; Eugenio Contreras. Responsable de investigación en Costa. ARAGÓN: Andrea Criado Frutos. Centro de Salud Piñera (Zaragoza); Michelle Cen- tro de Salud de Perpetuo Socorro (Huesca); Beatriz Sánchez Yago. Centro de Urgencias Hospital Obispo Polanco (Teruel); Carmen Quintana Velasco. Centro de Salud de Grañén (Huesca); Clara Cañete Alas- tuey. Centro de Salud de Perpetuo Socorro (Huesca); Clara Lanuzelli Barroso. Servicio de Urgencias Hospital Obispo Polanco (Teruel); Clara López Mas. Servicio de Urgencias Hospital Obispo Polanco (Teruel); Daniel Rubio Castro. Servicio de Medicina Interna Hospital Miguel Servet (Zaragoza); Laura Abad Pol. Centro de Salud Illueca, sector Calatayud (Zaragoza) BALEARES: Marina García Pardo. Centro de Salud de Inca (Mallorca) CANTABRIA: Arancha Rojo Calderón. Centro de Salud de Laredo (Cantabria); Carmen Toca Incera. Centro de Salud de La Victoria (Cantabria); Esperanza Rueda Alonso. Centro de Salud de Saja Cabuérniga (Cantabria); Helena Bermejo Ruiz. Centro de Salud de Valle de Villaverde (Cantabria); Juan Carlos López Caro. Centro de Salud Tomillo (Cantabria); Luis Sainz de Rozas Arpide. Centro de Salud de Santona (Cantabria); María Jesús Fernández Lerones. Centro de Salud de Altamira (Cantabria) GALICIA: Jaime González Rey. Centro de Salud de Matamá (Vigo); Gabriel Romero de Ávila Cabezas. Punto de Atención Continuada de La Guardia (Pontevedra); Carlos Chapela Villa. Centro de Salud de Matamá (Vigo); Ruth Otero González. Centro de Salud de Matamá (Vigo); Jose Ramón Parada Jorgal. Centro de Salud de Matamá (Vigo); Vicente Valle González. Centro de Salud de Las Nieves (Málaga); Maite Espantoso Romero. Punto de Atención Continuada de Vigo (Vigo); Susana Friande Pereira. Estructura Organizativa de Gestión Inte- grada de vigo (Vigo) MADRID: Alejandra Montero Costa. Centro de Salud de Fuencarral (Madrid); Alicia Jorge Formariz. Centro de Salud Luis Vives (Madrid); Ana Isabel Hernández Regalado. Centro de Salud de Valdemoro (Madrid); Ana Maria Rey López. Centro de Salud de Los Ángeles (Madrid); Ángel Alonso Val. Centro de Salud Luis Vives (Madrid); Ángel Luis Laguna. Centro de Salud de Los Ángeles (Madrid); Ángel Quijada Monzo. Centro de Salud Luis Vives (Madrid); Ángeles Casado Aguado. Centro de Salud Paseo Imperial (Madrid); Beata Bordyńska Michalska. Centro de Salud Luis Vives (Madrid); Beatriz Orozco Caratatal. Centro de Salud de Arazaca (Madrid); Beatriz Solans Aisa. Centro de Salud Luis Vives (Madrid); Carmen Mateo Pascual. Centro de Salud de Fuencarral (Madrid); Carmen Vieira Pascual. Centro de Salud La Plata (Madrid); Cristina Álvarez Alonso. Centro de Salud La Plata (Madrid); Cristina García Lombarda. Centro de Salud de Los Ángeles (Madrid); David González Gallardo. Centro de Salud Isabel II (Madrid); Dolores Morata Perelló. Centro de Salud de Villave de Salamanca (Madrid); Eleonora Valinoti. Centro de Salud Paseo Imperial (Madrid); Elisabet Astorga Garcia. Centro de Salud Cero del Aire (Madrid); Encarnación Santos Montalegre. Centro de Salud Los Cármenes (Madrid); Enrique Rodriguez de Mingor. Centro de Salud Las Armélicas (Madrid); Francisco Sánchez Martín. Centro de Salud Luis Vives (Madrid); Gloria Viñas Fernández. Centro de Salud Francia (Madrid) Guillermínez López Fernández. Centro de Salud de Villave de Salamanca (Madrid); Iziar Valero Infantes. Centro de Salud Las Ciudades (Madrid); Jaime María Cancha. Centro de Salud de Villave de Salamanca (Madrid); José Luis Martínez Carrao. Centro de Salud de Fuencarral (Madrid); José Ramón Sánchez Picón. Centro de Salud de Valdemoro (Madrid); Juan Carlos Moreno Fernández.
The authors declare that they have no competing interests.

Competing interests

The authors declare that they have no competing interests.
14. Roberts CM, Lopez-Campos JL, Pozo-Rodriguez F, Hart S, European CAT. European hospital adherence to GOLD recommendations for chronic obstructive pulmonary disease (COPD) exacerbation admissions. Thorax. 2013;68(12):1169–71.

15. Pozo-Rodriguez F, Castro-Acosta A, Alvarez CJ, Lopez-Campos JL, Forte A, Lopez-Quilez A, Agusti A, Abraira V, Group AS. Determinants of between-hospital variations in outcomes for patients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUDIOPC) in Spain. Int J Clin Pract. 2015;69(9):938–47.

16. Lopez-Campos JL, Abad Arranz M, Calero-Acuna C, Romero-Valero F, Ayeber-Garcia R, Hidalgo-Molina A, Aguilar-Perez-Gros RI, Garcia-Gil F, Casas-Maldonado F, Caballero-Ballesteros L, et al. Guideline adherence in outpatient clinics for chronic obstructive pulmonary disease: results from a clinical audit. PLoS One. 2016;11(3):e0151896.

17. Lopez-Campos JL, Hart S, Pozo-Rodriguez F, Roberts CM, European CAT. Variability of hospital resources for acute care of COPD patients: the European COPD audit. Eur Respir J. 2014;43(3):754–62.

18. Lundell S, Tistad M, Rehn B, Wiklund M, Holmner A, Wadell K. Building

19. Lopez-Campos JL, Abad Arranz M, Calero-Acuna C, Romero-Valero F, Ayeber-Garcia R, Hidalgo-Molina A, Aguilar-Perez-Gros RI, Garcia-Gil F, Casas-Maldonado F, Caballero-Ballesteros L, et al. Guideline adherence in outpatient clinics for chronic obstructive pulmonary disease: results from a clinical audit. PLoS One. 2016;11(3):e0151896.

20. Gruffydd-Jones K, Brusselle G, Jones R, Miravitlles M, Baldwin M, Stewart R, Stephenson A, Seitz D, Bell CM, Gruneir A, Gershon AS, Austin PC, Fu L, Fletcher CM. The clinical diagnosis of pulmonary emphysema; an executive summary. Am J Respir Crit Care Med. 2013;187(4):347–71.

21. Charlson ME, Pompei P, Ales KL, Macken ACE. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

22. Rio M, Reche S, Gutierrez F, et al. Determinants of overdiagnosis of COPD. Thorax. 2017;72(1):31–7.

23. Stephenson A, Seitz D, Bell CM, Gruneir A, Gershon AS, Austin PC, Fu L, Anderson GM, Rochon PA, Gill SS. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.

24. Segovia-Jiménez R, Maldonado F, Díaz-Herrera J, et al. Indacaterol-glycopyrronium versus tiotropium for stable chronic obstructive pulmonary disease: a randomized, double-blind, active-controlled trial. Eur Respir J. 2017;49(6):1711–23.

25. Lucke LJ, Ernst JR, et al. A population based study of chronic obstructive pulmonary disease: a crude analysis from a systematic review. Int J Chron Obstruct Pulmon Dis. 2017;12:987–76.

26. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.

27. Lopez-Campos JL, Marquez-Martín E, Ortega-Ruiza F, Triple therapy vs. triple therapy in COPD. Arch Bronconeumol. 2017;53(8):419–20.

28. Vogelmeier CF, Ciner CG, Martinez FJ, Aranzueco A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbrini LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53(3):128–49.

29. Wedzicha JA, Banejji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, et al. Indacaterol-Glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34.

30. Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keinger DL, Stewar R, Baldwin M, Jones RC. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–17.

31. Mapel D, Laliberte F, Roberts NH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, DuM RS, Patel J. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1825–36.

32. Um SW, Yoo CG, Kim YW, Han SK, Shin YS. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci. 2007;22(5):839–45.

33. Yang S, Lee L, Mallett S, Ayer J, Woltenholme A, Pascoe S. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. Adv Ther. 2015;32(2):157–71.

34. Ruparel M, Lopez-Campos JL, Castro-Acosta A, Hart S, Pozo-Rodriguez F, Roberts CM. Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit. ERJ Open Res. 2016;2(1).

35. Lopez-Campos JL, Abad Arranz M, Calero-Acuna C, Romero-Valero F, Ayeber-Garcia R, Hidalgo-Molina A, Aguilar-Perez-Gros RI, Garcia-Gil F, Casas-Maldonado F, Caballero-Ballesteros L, et al. Seasonal variability in clinical care of COPD outpatients: results from the Andalusian COPD audit. Int J Chron Obstruct Pulmon Dis. 2017;12:785–92.

36. Ivers N, Jamtvedt G, Flottorp S, Young JM, OGDgaard-Jensen J, French SD, OBrien MA, Johansen M, Grimshaw J, Osman AD. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2012;6(6):CD005229.

37. Mugford M, Banfield F, OHanlon M. Effects of feedback of information on clinical practice: a review. BMJ. 1991;303(6799):398–401.

38. Ospina MB, Micalis K, Deuchar L, Rowie BH, Leigh R, Bhutani M, Stickland MK. A systematic review of the effectiveness of discharge care bundles for patients with COPD. Thorax. 2017;72(1):31–9.

39. Lee TM, Tu K, Wing LL, Gershon AS. Identifying individuals with physician-diagnosed chronic obstructive pulmonary disease in primary care electronic medical records: a retrospective chart abstraction study. NPJ Prim Care Respir Med. 2017;27(1):22.

40. Lopez-Campos JL, Fernandez-Villar A, Calero-Acuna C, Represas-Represas C, Lopez-Ramirez C, Fernandez VL, Soler-Cataluna JJ, Casamor R, study g O-S. Evaluation of the COPD assessment test and GOLD patient types: a cross-sectional analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:975–84.

41. Miravitlles M, Soler-Cataluna JJ. GOLD in 2017: a view from the Spanish COPD guidelines (GesCOPD). Arch Bronconeumol. 2017;53(S8):89–90.